Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.
Identifieur interne : 000244 ( Main/Exploration ); précédent : 000243; suivant : 000245Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.
Auteurs : Katja Bauer [Allemagne] ; Ralf Dürrwald ; Michael Schlegel ; Kathrin Pfarr ; Dominik Topf ; Nadine Wiesener ; Hans-Martin Dahse ; Peter Wutzler ; Michaela SchmidtkeSource :
- Medical microbiology and immunology [ 1432-1831 ] ; 2012.
Descripteurs français
- KwdFr :
- Allemagne (MeSH), Animaux (MeSH), Antienzymes (pharmacologie), Antiviraux (pharmacologie), Humains (MeSH), Infections à Orthomyxoviridae (médecine vétérinaire), Infections à Orthomyxoviridae (virologie), Lignée cellulaire (MeSH), Maladies des porcs (virologie), Oséltamivir (pharmacologie), Résistance virale aux médicaments (MeSH), Sialidase (antagonistes et inhibiteurs), Sous-type H1N1 du virus de la grippe A (effets des médicaments et des substances chimiques), Sous-type H1N2 du virus de la grippe A (effets des médicaments et des substances chimiques), Sous-type H3N2 du virus de la grippe A (effets des médicaments et des substances chimiques), Suidae (MeSH), Tests de sensibilité microbienne (MeSH), Virus de la grippe A (classification), Virus de la grippe A (effets des médicaments et des substances chimiques), Virus de la grippe A (isolement et purification), Zanamivir (pharmacologie).
- MESH :
- antagonistes et inhibiteurs : Sialidase.
- effets des médicaments et des substances chimiques : Sous-type H1N1 du virus de la grippe A, Sous-type H1N2 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Virus de la grippe A.
- isolement et purification : Virus de la grippe A.
- médecine vétérinaire : Infections à Orthomyxoviridae.
- pharmacologie : Antienzymes, Antiviraux, Oséltamivir, Virus de la grippe A, Zanamivir.
- virologie : Infections à Orthomyxoviridae, Maladies des porcs.
- Allemagne, Animaux, Humains, Lignée cellulaire, Résistance virale aux médicaments, Suidae, Tests de sensibilité microbienne.
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Animals (MeSH), Antiviral Agents (pharmacology), Cell Line (MeSH), Drug Resistance, Viral (MeSH), Enzyme Inhibitors (pharmacology), Germany (MeSH), Humans (MeSH), Influenza A Virus, H1N1 Subtype (drug effects), Influenza A Virus, H1N2 Subtype (drug effects), Influenza A Virus, H3N2 Subtype (drug effects), Influenza A virus (classification), Influenza A virus (drug effects), Influenza A virus (isolation & purification), Microbial Sensitivity Tests (MeSH), Neuraminidase (antagonists & inhibitors), Orthomyxoviridae Infections (veterinary), Orthomyxoviridae Infections (virology), Oseltamivir (pharmacology), Swine (MeSH), Swine Diseases (virology), Zanamivir (pharmacology).
- MESH :
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , pharmacology : Antiviral Agents, Enzyme Inhibitors, Oseltamivir, Zanamivir.
- geographic : Germany.
- classification : Influenza A virus.
- drug effects : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H1N2 Subtype, Influenza A Virus, H3N2 Subtype, Influenza A virus.
- isolation & purification : Influenza A virus.
- veterinary : Orthomyxoviridae Infections.
- virology : Orthomyxoviridae Infections, Swine Diseases.
- Animals, Cell Line, Drug Resistance, Viral, Humans, Microbial Sensitivity Tests, Swine.
Abstract
European swine influenza A viruses donated the matrix protein 2 as well as the neuraminidase (NA) gene to pandemic influenza A (H1N1) viruses that emerged in 2009. As a result, the latter became amantadine resistant and neuraminidase inhibitor (NAI) susceptible. These recent developments reflecting the close connection between influenza A virus infection chains in humans and pigs urge an antiviral surveillance within swine influenza A viruses. Here, NAI susceptibility of 204 serologically typed swine influenza A viruses of subtypes H1N1, H1N2, and H3N2 circulating in Germany between 1981 and 2008 was analyzed in chemiluminescence-based NA inhibition assays. Mean 50% inhibitory concentrations of oseltamivir and zanamivir indicate a good drug susceptibility of tested viruses. As found for human isolates, the oseltamivir and zanamivir susceptibility was subtype-specific. So, swine influenza A (H1N1) viruses were just as susceptible to oseltamivir as to zanamivir. In contrast, swine H1N2 and H3N2 influenza A viruses were more sensitive to oseltamivir than to zanamivir. Furthermore, reduction in plaque size and virus spread by both drugs was tested with selected H1N1 and H1N2 isolates in MDCK cells expressing similar amounts of α2.3- and α2.6-linked sialic acid receptors. Data obtained in cell culture-based assays for H1N1 isolates correlated with that from enzyme inhibition assays. But, H1N2 isolates that are additionally glycosylated at Asn158 and Asn163 near the receptor-binding site of hemagglutinin (HA) were resistant to both NAI in MDCK cells. Possibly, these additional HA glycosylations cause a misbalance between HA and NA function that hampers or abolishes NAI activity in cells.
DOI: 10.1007/s00430-011-0206-1
PubMed: 21688167
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.</title><author><name sortKey="Bauer, Katja" sort="Bauer, Katja" uniqKey="Bauer K" first="Katja" last="Bauer">Katja Bauer</name><affiliation wicri:level="1"><nlm:affiliation>School of Medicine, Department of Virology and Antiviral Therapy, Jena University Hospital, Jena, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>School of Medicine, Department of Virology and Antiviral Therapy, Jena University Hospital, Jena</wicri:regionArea><wicri:noRegion>Jena</wicri:noRegion><wicri:noRegion>Jena</wicri:noRegion><wicri:noRegion>Jena</wicri:noRegion></affiliation></author><author><name sortKey="Durrwald, Ralf" sort="Durrwald, Ralf" uniqKey="Durrwald R" first="Ralf" last="Dürrwald">Ralf Dürrwald</name></author><author><name sortKey="Schlegel, Michael" sort="Schlegel, Michael" uniqKey="Schlegel M" first="Michael" last="Schlegel">Michael Schlegel</name></author><author><name sortKey="Pfarr, Kathrin" sort="Pfarr, Kathrin" uniqKey="Pfarr K" first="Kathrin" last="Pfarr">Kathrin Pfarr</name></author><author><name sortKey="Topf, Dominik" sort="Topf, Dominik" uniqKey="Topf D" first="Dominik" last="Topf">Dominik Topf</name></author><author><name sortKey="Wiesener, Nadine" sort="Wiesener, Nadine" uniqKey="Wiesener N" first="Nadine" last="Wiesener">Nadine Wiesener</name></author><author><name sortKey="Dahse, Hans Martin" sort="Dahse, Hans Martin" uniqKey="Dahse H" first="Hans-Martin" last="Dahse">Hans-Martin Dahse</name></author><author><name sortKey="Wutzler, Peter" sort="Wutzler, Peter" uniqKey="Wutzler P" first="Peter" last="Wutzler">Peter Wutzler</name></author><author><name sortKey="Schmidtke, Michaela" sort="Schmidtke, Michaela" uniqKey="Schmidtke M" first="Michaela" last="Schmidtke">Michaela Schmidtke</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:21688167</idno><idno type="pmid">21688167</idno><idno type="doi">10.1007/s00430-011-0206-1</idno><idno type="wicri:Area/Main/Corpus">000280</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000280</idno><idno type="wicri:Area/Main/Curation">000280</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000280</idno><idno type="wicri:Area/Main/Exploration">000280</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.</title><author><name sortKey="Bauer, Katja" sort="Bauer, Katja" uniqKey="Bauer K" first="Katja" last="Bauer">Katja Bauer</name><affiliation wicri:level="1"><nlm:affiliation>School of Medicine, Department of Virology and Antiviral Therapy, Jena University Hospital, Jena, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>School of Medicine, Department of Virology and Antiviral Therapy, Jena University Hospital, Jena</wicri:regionArea><wicri:noRegion>Jena</wicri:noRegion><wicri:noRegion>Jena</wicri:noRegion><wicri:noRegion>Jena</wicri:noRegion></affiliation></author><author><name sortKey="Durrwald, Ralf" sort="Durrwald, Ralf" uniqKey="Durrwald R" first="Ralf" last="Dürrwald">Ralf Dürrwald</name></author><author><name sortKey="Schlegel, Michael" sort="Schlegel, Michael" uniqKey="Schlegel M" first="Michael" last="Schlegel">Michael Schlegel</name></author><author><name sortKey="Pfarr, Kathrin" sort="Pfarr, Kathrin" uniqKey="Pfarr K" first="Kathrin" last="Pfarr">Kathrin Pfarr</name></author><author><name sortKey="Topf, Dominik" sort="Topf, Dominik" uniqKey="Topf D" first="Dominik" last="Topf">Dominik Topf</name></author><author><name sortKey="Wiesener, Nadine" sort="Wiesener, Nadine" uniqKey="Wiesener N" first="Nadine" last="Wiesener">Nadine Wiesener</name></author><author><name sortKey="Dahse, Hans Martin" sort="Dahse, Hans Martin" uniqKey="Dahse H" first="Hans-Martin" last="Dahse">Hans-Martin Dahse</name></author><author><name sortKey="Wutzler, Peter" sort="Wutzler, Peter" uniqKey="Wutzler P" first="Peter" last="Wutzler">Peter Wutzler</name></author><author><name sortKey="Schmidtke, Michaela" sort="Schmidtke, Michaela" uniqKey="Schmidtke M" first="Michaela" last="Schmidtke">Michaela Schmidtke</name></author></analytic><series><title level="j">Medical microbiology and immunology</title><idno type="eISSN">1432-1831</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Antiviral Agents (pharmacology)</term><term>Cell Line (MeSH)</term><term>Drug Resistance, Viral (MeSH)</term><term>Enzyme Inhibitors (pharmacology)</term><term>Germany (MeSH)</term><term>Humans (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (drug effects)</term><term>Influenza A Virus, H1N2 Subtype (drug effects)</term><term>Influenza A Virus, H3N2 Subtype (drug effects)</term><term>Influenza A virus (classification)</term><term>Influenza A virus (drug effects)</term><term>Influenza A virus (isolation & purification)</term><term>Microbial Sensitivity Tests (MeSH)</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Orthomyxoviridae Infections (veterinary)</term><term>Orthomyxoviridae Infections (virology)</term><term>Oseltamivir (pharmacology)</term><term>Swine (MeSH)</term><term>Swine Diseases (virology)</term><term>Zanamivir (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Allemagne (MeSH)</term><term>Animaux (MeSH)</term><term>Antienzymes (pharmacologie)</term><term>Antiviraux (pharmacologie)</term><term>Humains (MeSH)</term><term>Infections à Orthomyxoviridae (médecine vétérinaire)</term><term>Infections à Orthomyxoviridae (virologie)</term><term>Lignée cellulaire (MeSH)</term><term>Maladies des porcs (virologie)</term><term>Oséltamivir (pharmacologie)</term><term>Résistance virale aux médicaments (MeSH)</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Sous-type H1N1 du virus de la grippe A (effets des médicaments et des substances chimiques)</term><term>Sous-type H1N2 du virus de la grippe A (effets des médicaments et des substances chimiques)</term><term>Sous-type H3N2 du virus de la grippe A (effets des médicaments et des substances chimiques)</term><term>Suidae (MeSH)</term><term>Tests de sensibilité microbienne (MeSH)</term><term>Virus de la grippe A (classification)</term><term>Virus de la grippe A (effets des médicaments et des substances chimiques)</term><term>Virus de la grippe A (isolement et purification)</term><term>Zanamivir (pharmacologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Enzyme Inhibitors</term><term>Oseltamivir</term><term>Zanamivir</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Germany</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H1N2 Subtype</term><term>Influenza A Virus, H3N2 Subtype</term><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H1N2 du virus de la grippe A</term><term>Sous-type H3N2 du virus de la grippe A</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="médecine vétérinaire" xml:lang="fr"><term>Infections à Orthomyxoviridae</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antienzymes</term><term>Antiviraux</term><term>Oséltamivir</term><term>Virus de la grippe A</term><term>Zanamivir</term></keywords><keywords scheme="MESH" qualifier="veterinary" xml:lang="en"><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à Orthomyxoviridae</term><term>Maladies des porcs</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Orthomyxoviridae Infections</term><term>Swine Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Drug Resistance, Viral</term><term>Humans</term><term>Microbial Sensitivity Tests</term><term>Swine</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Allemagne</term><term>Animaux</term><term>Humains</term><term>Lignée cellulaire</term><term>Résistance virale aux médicaments</term><term>Suidae</term><term>Tests de sensibilité microbienne</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">European swine influenza A viruses donated the matrix protein 2 as well as the neuraminidase (NA) gene to pandemic influenza A (H1N1) viruses that emerged in 2009. As a result, the latter became amantadine resistant and neuraminidase inhibitor (NAI) susceptible. These recent developments reflecting the close connection between influenza A virus infection chains in humans and pigs urge an antiviral surveillance within swine influenza A viruses. Here, NAI susceptibility of 204 serologically typed swine influenza A viruses of subtypes H1N1, H1N2, and H3N2 circulating in Germany between 1981 and 2008 was analyzed in chemiluminescence-based NA inhibition assays. Mean 50% inhibitory concentrations of oseltamivir and zanamivir indicate a good drug susceptibility of tested viruses. As found for human isolates, the oseltamivir and zanamivir susceptibility was subtype-specific. So, swine influenza A (H1N1) viruses were just as susceptible to oseltamivir as to zanamivir. In contrast, swine H1N2 and H3N2 influenza A viruses were more sensitive to oseltamivir than to zanamivir. Furthermore, reduction in plaque size and virus spread by both drugs was tested with selected H1N1 and H1N2 isolates in MDCK cells expressing similar amounts of α2.3- and α2.6-linked sialic acid receptors. Data obtained in cell culture-based assays for H1N1 isolates correlated with that from enzyme inhibition assays. But, H1N2 isolates that are additionally glycosylated at Asn158 and Asn163 near the receptor-binding site of hemagglutinin (HA) were resistant to both NAI in MDCK cells. Possibly, these additional HA glycosylations cause a misbalance between HA and NA function that hampers or abolishes NAI activity in cells.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21688167</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1831</ISSN><JournalIssue CitedMedium="Internet"><Volume>201</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Medical microbiology and immunology</Title><ISOAbbreviation>Med. Microbiol. Immunol.</ISOAbbreviation></Journal><ArticleTitle>Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.</ArticleTitle><Pagination><MedlinePgn>61-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00430-011-0206-1</ELocationID><Abstract><AbstractText>European swine influenza A viruses donated the matrix protein 2 as well as the neuraminidase (NA) gene to pandemic influenza A (H1N1) viruses that emerged in 2009. As a result, the latter became amantadine resistant and neuraminidase inhibitor (NAI) susceptible. These recent developments reflecting the close connection between influenza A virus infection chains in humans and pigs urge an antiviral surveillance within swine influenza A viruses. Here, NAI susceptibility of 204 serologically typed swine influenza A viruses of subtypes H1N1, H1N2, and H3N2 circulating in Germany between 1981 and 2008 was analyzed in chemiluminescence-based NA inhibition assays. Mean 50% inhibitory concentrations of oseltamivir and zanamivir indicate a good drug susceptibility of tested viruses. As found for human isolates, the oseltamivir and zanamivir susceptibility was subtype-specific. So, swine influenza A (H1N1) viruses were just as susceptible to oseltamivir as to zanamivir. In contrast, swine H1N2 and H3N2 influenza A viruses were more sensitive to oseltamivir than to zanamivir. Furthermore, reduction in plaque size and virus spread by both drugs was tested with selected H1N1 and H1N2 isolates in MDCK cells expressing similar amounts of α2.3- and α2.6-linked sialic acid receptors. Data obtained in cell culture-based assays for H1N1 isolates correlated with that from enzyme inhibition assays. But, H1N2 isolates that are additionally glycosylated at Asn158 and Asn163 near the receptor-binding site of hemagglutinin (HA) were resistant to both NAI in MDCK cells. Possibly, these additional HA glycosylations cause a misbalance between HA and NA function that hampers or abolishes NAI activity in cells.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Katja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>School of Medicine, Department of Virology and Antiviral Therapy, Jena University Hospital, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dürrwald</LastName><ForeName>Ralf</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Schlegel</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pfarr</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Topf</LastName><ForeName>Dominik</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Wiesener</LastName><ForeName>Nadine</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Dahse</LastName><ForeName>Hans-Martin</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Wutzler</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Schmidtke</LastName><ForeName>Michaela</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Med Microbiol Immunol</MedlineTA><NlmUniqueID>0314524</NlmUniqueID><ISSNLinking>0300-8584</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6O3XI777I</RegistryNumber><NameOfSubstance UI="D053243">Zanamivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057221" MajorTopicYN="N">Influenza A Virus, H1N2 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName><QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013553" MajorTopicYN="N">Swine Diseases</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053243" MajorTopicYN="N">Zanamivir</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>03</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21688167</ArticleId><ArticleId IdType="doi">10.1007/s00430-011-0206-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Virol. 2008 Jan;41(1):13-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18055254</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2010 Sep;54(9):3671-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20585136</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1983 Sep;129(2):521-3</Citation><ArticleIdList><ArticleId IdType="pubmed">6623931</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Inst Pasteur Virol. 1988 Oct-Dec;139(4):429-37</Citation><ArticleIdList><ArticleId IdType="pubmed">3214596</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1998 Nov;178(5):1257-62</Citation><ArticleIdList><ArticleId IdType="pubmed">9780244</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009 Jul 28;4(7):e6402</Citation><ArticleIdList><ArticleId IdType="pubmed">19636415</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1997 Jun 9;232(2):310-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9191844</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2009 Apr;82(1):34-41</Citation><ArticleIdList><ArticleId IdType="pubmed">19428593</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2006 Jun 15;193(12):1626-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16703504</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2011 Jan 1;203(1):13-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21148491</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Rec. 1995 Apr 1;136(13):328-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7541591</ArticleId></ArticleIdList></Reference><Reference><Citation>Antivir Ther. 2010;15(8):1151-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21149922</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1997 Nov;71(11):8377-84</Citation><ArticleIdList><ArticleId IdType="pubmed">9343193</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2009 Jul 10;325(5937):140-1</Citation><ArticleIdList><ArticleId IdType="pubmed">19589977</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92</Citation><ArticleIdList><ArticleId IdType="pubmed">18625765</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2006 Jul;50(7):2395-402</Citation><ArticleIdList><ArticleId IdType="pubmed">16801417</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 2005 Aug;43(8):4139-46</Citation><ArticleIdList><ArticleId IdType="pubmed">16081961</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2009 Apr;90(Pt 4):900-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19223487</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Microbiol Immunol. 2007 Dec;196(4):203-12</Citation><ArticleIdList><ArticleId IdType="pubmed">17431677</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2000 Jul;47(1):1-17</Citation><ArticleIdList><ArticleId IdType="pubmed">10930642</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2007 Jul 15;196(2):249-57</Citation><ArticleIdList><ArticleId IdType="pubmed">17570112</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2000 Sep;74(18):8502-12</Citation><ArticleIdList><ArticleId IdType="pubmed">10954551</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Med Virol. 2002 May-Jun;12(3):159-66</Citation><ArticleIdList><ArticleId IdType="pubmed">11987141</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2005 Sep 29;353(13):1363-73</Citation><ArticleIdList><ArticleId IdType="pubmed">16192481</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1999 Sep 15;262(1):31-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10489338</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1994 Oct;204(1):453-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8091678</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Cell Mol Biol. 1996 Jan;14(1):104-12</Citation><ArticleIdList><ArticleId IdType="pubmed">8534481</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2003 Jul;47(7):2264-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12821478</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Virol. 2003 Apr;148(4):793-802</Citation><ArticleIdList><ArticleId IdType="pubmed">12664301</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1993 Mar;193(1):503-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8438586</ArticleId></ArticleIdList></Reference><Reference><Citation>J Formos Med Assoc. 2009 Jul;108(7):526-32</Citation><ArticleIdList><ArticleId IdType="pubmed">19586825</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2007 Aug;75(2):173-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17350111</ArticleId></ArticleIdList></Reference><Reference><Citation>Intervirology. 2006;49(5):286-93</Citation><ArticleIdList><ArticleId IdType="pubmed">16809934</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2000 Jan;44(1):78-87</Citation><ArticleIdList><ArticleId IdType="pubmed">10602727</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Sep;79(17):11533-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16103207</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoonoses Public Health. 2009 Aug;56(6-7):310-25</Citation><ArticleIdList><ArticleId IdType="pubmed">19497089</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2004 Jul;103(1-2):199-203</Citation><ArticleIdList><ArticleId IdType="pubmed">15163510</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2009 Jul 10;325(5937):197-201</Citation><ArticleIdList><ArticleId IdType="pubmed">19465683</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Virol. 2008;153(11):2085-92</Citation><ArticleIdList><ArticleId IdType="pubmed">18985274</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Oct;79(19):12416-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16160169</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1997 Jun 9;232(2):345-50</Citation><ArticleIdList><ArticleId IdType="pubmed">9191848</ArticleId></ArticleIdList></Reference><Reference><Citation>Intervirology. 2003;46(1):66-70</Citation><ArticleIdList><ArticleId IdType="pubmed">12566701</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2009 Aug 20;460(7258):1021-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19672242</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1998 Sep;72(9):7367-73</Citation><ArticleIdList><ArticleId IdType="pubmed">9696833</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 1998 Dec;79 ( Pt 12):2947-55</Citation><ArticleIdList><ArticleId IdType="pubmed">9880008</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2010 Jan 28;53(2):778-86</Citation><ArticleIdList><ArticleId IdType="pubmed">20014777</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2008 Apr 11;4(4):e1000043</Citation><ArticleIdList><ArticleId IdType="pubmed">18404209</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2007 Sep;75(3):219-26</Citation><ArticleIdList><ArticleId IdType="pubmed">17445913</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Virol. 2001 Dec;146(12):2275-89</Citation><ArticleIdList><ArticleId IdType="pubmed">11811679</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1997 Jun 23;233(1):224-34</Citation><ArticleIdList><ArticleId IdType="pubmed">9201232</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2001 Apr 10;282(2):301-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11289812</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Mar 5;360(10):953-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19258250</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull World Health Organ. 1981;59(1):75-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6973418</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Med Virol. 2000 Jan-Feb;10(1):45-55</Citation><ArticleIdList><ArticleId IdType="pubmed">10654004</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Aug;77(15):8418-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12857911</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2009 Jun 25;459(7250):1122-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19516283</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2009 Sep;3(5):207-13</Citation><ArticleIdList><ArticleId IdType="pubmed">19768134</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2009 Apr;15(4):552-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19331731</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2008 Jan;89(Pt 1):271-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18089751</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2005 Oct 1;366(9492):1175-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16198766</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Mar 19;303(5665):1838-42</Citation><ArticleIdList><ArticleId IdType="pubmed">14764886</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Sep 7;443(7107):45-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16915235</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Microbiol Immunol. 2009 Aug;198(3):175-83</Citation><ArticleIdList><ArticleId IdType="pubmed">19543913</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2009 Feb 19;14(7):null</Citation><ArticleIdList><ArticleId IdType="pubmed">19232228</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2001 Feb 15;183(4):523-31</Citation><ArticleIdList><ArticleId IdType="pubmed">11170976</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2005 Feb;86(Pt 2):423-33</Citation><ArticleIdList><ArticleId IdType="pubmed">15659762</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2005 Dec;114(1-2):15-22</Citation><ArticleIdList><ArticleId IdType="pubmed">15996787</ArticleId></ArticleIdList></Reference><Reference><Citation>Intervirology. 2004;47(2):72-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15192270</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 1993 Jul;37(7):1473-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8363379</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2002 Oct 15;186(8):1074-80</Citation><ArticleIdList><ArticleId IdType="pubmed">12355356</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1991 Jun;65(6):3022-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2033664</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2006 Feb 22;295(8):891-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16456087</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country></list><tree><noCountry><name sortKey="Dahse, Hans Martin" sort="Dahse, Hans Martin" uniqKey="Dahse H" first="Hans-Martin" last="Dahse">Hans-Martin Dahse</name><name sortKey="Durrwald, Ralf" sort="Durrwald, Ralf" uniqKey="Durrwald R" first="Ralf" last="Dürrwald">Ralf Dürrwald</name><name sortKey="Pfarr, Kathrin" sort="Pfarr, Kathrin" uniqKey="Pfarr K" first="Kathrin" last="Pfarr">Kathrin Pfarr</name><name sortKey="Schlegel, Michael" sort="Schlegel, Michael" uniqKey="Schlegel M" first="Michael" last="Schlegel">Michael Schlegel</name><name sortKey="Schmidtke, Michaela" sort="Schmidtke, Michaela" uniqKey="Schmidtke M" first="Michaela" last="Schmidtke">Michaela Schmidtke</name><name sortKey="Topf, Dominik" sort="Topf, Dominik" uniqKey="Topf D" first="Dominik" last="Topf">Dominik Topf</name><name sortKey="Wiesener, Nadine" sort="Wiesener, Nadine" uniqKey="Wiesener N" first="Nadine" last="Wiesener">Nadine Wiesener</name><name sortKey="Wutzler, Peter" sort="Wutzler, Peter" uniqKey="Wutzler P" first="Peter" last="Wutzler">Peter Wutzler</name></noCountry><country name="Allemagne"><noRegion><name sortKey="Bauer, Katja" sort="Bauer, Katja" uniqKey="Bauer K" first="Katja" last="Bauer">Katja Bauer</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000244 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000244 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeAllemagneV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21688167
|texte= Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21688167" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV4
| This area was generated with Dilib version V0.6.35. |  |